长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry suspension for domestic production [1] Group 1 - Jinsai Pharmaceutical's GS3-007a is an orally administered small molecule growth hormone secretagogue developed independently by the company [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of idiopathic short stature (ISS) [1]